Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
J Thorac Cardiovasc Surg. 2018 May;155(5):2096-2102. doi: 10.1016/j.jtcvs.2017.10.054. Epub 2017 Oct 27.
Residual midventricular obstruction after transaortic myectomy may lead to recurrent symptoms and reoperation in patients with hypertrophic cardiomyopathy and long-segment septal hypertrophy. A combined transaortic and transapical approach to septal myectomy during initial operation allows for the complete relief of subaortic and midventricular gradients and may reduce the risk of poor late functional results.
We analyzed the early outcomes of 86 patients aged 18 years or more who underwent combined transaortic and transapical septal myectomy for left ventricular outflow tract obstruction due to systolic anterior motion and midventricular obstruction or cavitary obliteration due to apical hypertrophic cardiomyopathy.
Midventricular obstruction was present in 59 patients (68.6%); 12 patients (14.0%) had cavitary obliteration, and 15 patients (17.4%) had a combination of both. Overall, median (25th, 75th percentile) prebypass and postbypass directly measured intracavitary gradients were 85 mm Hg (48, 125) and 4 mm Hg (0, 10.8), respectively; median predischarge transthoracic left ventricular outflow tract and midventricular gradients were 0 mm Hg (0, 0) and 0 mm Hg (0, 8.5). Median crossclamp and perfusion times were 35 minutes (27, 44) and 48.5 minutes (40, 64). The 30-day and 1-year survivals were both 95%, with 2 early deaths. Functional status beyond 30 days postoperatively was available in 42 patients, and 41 patients reported improvement in symptoms and were in New York Heart Association class I/II.
Combined transaortic and transapical septal myectomy is an effective and reasonably safe approach for patients with hypertrophic cardiomyopathy with complex septal hypertrophy. This method may prevent residual midventricular obstruction and permits myectomy to augment diastolic filling and improve left ventricular stroke volume in patients with apical hypertrophic cardiomyopathy.
主动脉瓣下肌切除术(aortic valve myectomy,AVM)后残余的室中隔梗阻可能导致肥厚型心肌病(hypertrophic cardiomyopathy,HCM)和长节段室间隔肥厚患者出现症状复发和再次手术。初次手术时采用经主动脉瓣和经心尖联合方法进行室间隔切除术(septal myectomy,SM)可完全缓解主动脉瓣下和室中隔压力阶差,并可能降低不良晚期功能结果的风险。
我们分析了 86 例年龄在 18 岁及以上的患者的早期结果,这些患者因收缩期前向运动和室中隔梗阻而行经主动脉瓣和经心尖联合 SM 治疗左心室流出道梗阻,或因心尖部肥厚型心肌病而行室腔闭塞术(cavitary obliteration,CO)。
59 例(68.6%)患者存在室中隔梗阻;12 例(14.0%)患者存在 CO,15 例(17.4%)患者两者兼有。总的来说,体外循环前和体外循环后的直接测量心腔内压力阶差中位数(25%,75%分位数)分别为 85mmHg(48,125)和 4mmHg(0,10.8);出院前经胸左心室流出道和室中隔压力阶差中位数分别为 0mmHg(0,0)和 0mmHg(0,8.5)。体外循环夹闭时间和灌注时间中位数分别为 35 分钟(27,44)和 48.5 分钟(40,64)。30 天和 1 年生存率均为 95%,有 2 例早期死亡。42 例患者术后 30 天以上的功能状态可用,41 例患者报告症状改善,并处于纽约心脏协会(New York Heart Association,NYHA)心功能Ⅰ/Ⅱ级。
对于伴有复杂室间隔肥厚的 HCM 患者,经主动脉瓣和经心尖联合 SM 是一种有效且相对安全的方法。这种方法可预防残余室中隔梗阻,并允许 SM 增加舒张期充盈,改善心尖部肥厚型心肌病患者的左心室每搏量。